Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma

Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma
复制标题

DOI:
10.1016/j.humpath.2015.06.018
复制
发表时间:
2015-10-01
期刊:
影响因子:
3.3
通讯作者:
Kim, Jang-Hee
Kim, Jang-Hee
中科院分区:
医学3区
文献类型:
--
作者:
Choi, Yong Won;Kim, Young Hwa;Kim, Jang-Hee

文献摘要

被引文献

相似文献

中期因子是一种多功能的肝素结合生长因子,经常在恶性肿瘤患者中表达,但在健康成人中检测不到。在各种癌症中,中期因子的高表达与侵袭性临床行为和不良预后相关。在本研究中,我们研究了中期因子在甲状腺乳头状癌(PTC)中的表达,并评估了其与BRAFV600E突变和临床病理参数的关系。我们确定了79例PTC中BRAFV600E突变的存在,并研究了BRAFV600E突变对原代甲状腺细胞中期因子表达的影响。此外,我们评估了中期因子表达与各种临床病理参数之间的关联。我们发现中期因子在BRAFV 600 E PTC中的表达频率(68.3%)高于BRAF野生型PTC(18.8%)。BRAFV600E转导可上调原代甲状腺细胞中期因子的表达。此外,中期因子表达与BRAFV 600 E PTC的多个淋巴结(>= 5)转移相关。总之,我们的结果表明,中期因子表达可能是预测BRAFV 600 E PTC中存在多个淋巴结转移的临床有用标志物。(C)2015 Elsevier Inc. All rights reserved.
Midkine is a multifunctional, heparin-binding growth factor that is frequently expressed in patients with malignancies but is undetectable in healthy adults. In various cancers, high expression of midkine is associated with aggressive clinical behavior and a poor prognosis. In the present study, we investigated the expression of midkine in papillary thyroid carcinoma (PTC) and assessed its association with a BRAFV600E mutation and the clinicopathological parameters. We determined the presence of a BRAFV600E mutation in 79 cases of PTC and examined the effects of the BRAFV600E mutation on midkine expression in primary thyrocytes. In addition, we evaluated the association between midkine expression and various clinicopathological parameters. We found that midkine is more frequently expressed in BRAFV600E PTC (68.3%) than in BRAF wild-type PTC (18.8%). BRAFV600E transduction could up-regulate midkine expression in primary thyrocytes. Moreover, midkine expression was associated with multiple lymph node (>= 5) metastases in BRAFV600E PTC. In conclusion, our results suggest that midkine expression could be a clinically useful marker in predicting the presence of multiple lymph node metastases in BRAFV600E PTC. (C) 2015 Elsevier Inc. All rights reserved.